


Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/586,072	
			Filing Date		
			First Named Inventor	BROUGH, Douglas E.	
			Group Art Unit	1632	
			Examiner Name		
Sheet	1	of	11	Attorney Docket Number	253625

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Document Number	Kind Code			
	AA	US- 4,797,368		01-10-1989	Carter et al.	
	AB	US- 5,543,328		08-06-1996	McClelland et al.	
	AC	US- 5,559,099		09-24-1996	Wickham et al.	
	AD	US- 5,712,136		01-27-1998	Wickham et al.	
	AE	US- 5,731,190		03-24-1998	Wickham et al.	
	AF	US- 5,756,086		05-26-1998	McClelland et al.	
	AG	US- 5,770,442		06-23-1998	Wickham et al.	
	AH	US- 5,801,030		09-01-1998	McVey et al.	
	AI	US- 5,804,413		09-08-1998	DeLuca	
	AJ	US- 5,837,511		11-17-1998	Falck-Pedersen et al.	
	AK	US- 5,837,532		11-17-1998	Preston et al.	
	AL	US- 5,840,686		11-24-1998	Chader et al.	
	AM	US- 5,846,782		12-08-1998	Wickham et al.	
	AN	US- 5,849,561		12-15-1998	Falck-Pedersen	
	AO	US- 5,849,572		12-15-1998	Glorioso et al.	
	AP	US- 5,851,806		12-22-1998	Kovesdi et al.	
	AQ	US- 5,871,727		02-16-1999	Curiel	
	AR	US- 5,885,808		03-23-1999	Spooner et al.	
	AS	US- 5,922,315		07-13-1999	Roy	

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/586,072	
			Filing Date		
			First Named Inventor	BROUGH, Douglas E.	
			Group Art Unit	1632	
			Examiner Name		
Sheet	2	of	11	Attorney Docket Number	253625

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Document Number	Kind Code			
	AT	US- 5,962,311		10-05-1999	Wickham et al.	
	AU	US- 5,965,358		10-12-1999	Carrión et al.	
	AV	US- 5,965,541		10-12-1999	Wickham et al.	
	AW	US- 5,994,106		11-30-1999	Kovesdi et al.	
	AX	US- 5,994,128		11-30-1999	Fallaux et al.	
	AY	US- 6,033,908		03-07-2000	Bout et al.	
	AZ	US- 6,057,155		05-02-2000	Wickham et al.	
	BA	US- 6,063,627		05-16-2000	McVey et al.	
	BB	US- 6,127,525		10-03-2000	Crystal et al.	
	BC	US- 6,153,435		11-28-2000	Crystal et al.	
	BD	US- 6,165,754		12-26-2000	Crystal et al.	
	BE	US- 6,168,941		01-02-2001	Liu et al.	
	BF	US- 6,225,113		05-01-2001	Brough et al.	
	BG	US- 6,228,646		05-08-2001	Hardy	
	BH	US- 6,329,190		12-11-2001	Wickham et al.	
	BI	US- 6,329,200		12-11-2001	McVey et al.	
	BJ	US- 6,383,795		05-07-2002	Carrión et al.	
	BK	US- 6,440,728		08-27-2002	McVey et al.	
	BL	US- 6,447,995		09-10-2002	Carrión et al.	
	BM	US- 6,455,314		09-24-2002	Wickham et al.	

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/586,072	
			Filing Date		
			First Named Inventor	BROUGH, Douglas E.	
			Group Art Unit	1632	
			Examiner Name		
Sheet	3	of	11	Attorney Docket Number	253625

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Document Number	Kind Code			
	BN	US- 6,465,253		10-15-2002	Wickham et al.	
	BO	US- 6,475,757		11-05-2002	McVey et al.	
	BP	US- 6,482,616		11-19-2002	Kovesdi et al.	
	BQ	US- 6,576,456		06-10-2003	Wickham et al.	
	BR	US- 6,649,373		11-18-2003	Brough et al.	
	BS	US- 6,660,521		12-09-2003	Brough et al.	
	BT	US- 2001/0043922	A1	11-22-2001	Kovesdi et al.	
	BU	US- 2001/0047081	A1	11-29-2001	Roelvink et al.	
	BV	US- 2002/0004040	A1	01-10-2002	Kovesdi et al.	
	BW	US- 2002/0031831	A1	03-14-2002	Kovesdi et al.	
	BX	US- 2002/0034735	A1	03-21-2002	Carrión et al.	
	BY	US- 2002/0099024	A1	07-25-2002	Wickham et al.	
	BZ	US- 2002/0110545	A1	08-15-2002	Kovesdi et al.	
	CA	US- 2002/0151027	A1	10-17-2002	Wickham et al.	
	CB	US- 2003/0099619	A1	05-29-2003	Wickham et al.	


FOREIGN PATENT DOCUMENTS									
Examiner Initials ¹	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided**	
		Office	Number	Kind Code				Yes	No
	CC	WO	91/02788	A	03-07-1991	University of Glasgow			
	CD	WO	93/24529	A	12-09-1993	Univ. Southern California			

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/586,072
				Filing Date	
				First Named Inventor	BROUGH, Douglas E.
				Group Art Unit	1632
				Examiner Name	
Sheet	4	of	11	Attorney Docket Number	253625


FOREIGN PATENT DOCUMENTS									
Examiner Initials ¹	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided**	
		Office	Number	Kind Code				Yes	No
	CE	WO	95/34671	A	12-21-1995	GenVec, Inc.			
	CF	WO	96/04394	A	02-15-1996	Medical Research Council			
	CG	WO	96/07734	A	03-14-1996	GenVec, Inc.			
	CH	WO	96/26281	A	08-29-1996	GenVec, Inc.			
	CI	WO	97/00326	A	01-03-1997	Introgene BV et al.			
	CJ	WO	97/09439	A	03-13-1997	GenVec, Inc.			
	CK	WO	97/12986	A	04-10-1997	Cornell Res. Foundation			
	CL	WO	97/20051	A	06-06-1997	GenVec, Inc.			
	CM	WO	97/21826	A	06-19-1997	GenVec, Inc.			
	CN	WO	97/30722	A	08-28-1997	Amgen, Inc.			
	CO	WO	98/07865	A	02-26-1998	GenVec, Inc.			
	CP	WO	98/07877	A	02-26-1998	GenVec, Inc.			
	CQ	WO	98/15637	A	04-16-1998	University of Pittsburgh			
	CR	WO	98/40509	A	09-17-1998	Cornell Res. Foundation			
	CS	WO	98/53087	A	11-26-1998	Cornell Res. Foundation			
	CT	WO	98/54346	A	12-03-1998	GenVec, Inc.			
	CU	WO	98/56937	A	12-17-1998	GenVec, Inc.			
	CV	WO	99/04806	A	02-04-1999	Northwestern University			
	CW	WO	99/06583	A	02-11-1999	University of Pittsburgh			
	CX	WO	99/15686	A	04-01-1999	GenVec, Inc.			

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/586,072	
			Filing Date		
			First Named Inventor	BROUGH, Douglas E.	
			Group Art Unit	1632	
Examiner Name					
Sheet	5	of	11	Attorney Docket Number	253625

FOREIGN PATENT DOCUMENTS									
Examiner Initials ¹	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided**	
		Office	Number	Kind Code				Yes	No
	CY	WO	99/54441	A	10-28-1999	GenVec, Inc.			
	CZ	WO	00/00628	A	01-06-2000	GenVec, Inc.			
	DA	WO	00/12765	A	03-09-2000	GenVec, Inc.			
	DB	WO	00/15823	A	03-23-2000	GenVec, Inc.			
	DC	WO	00/34496	A	06-15-2000	GenVec, Inc.			
	DD	WO	00/73764	A	12-07-2000	Baylor Coll. of Medicine			
	DE	WO	01/58494	A	08-16-2001	GenVec, Inc. et al.			
	DF	WO	01/58940	A	08-16-2001	GenVec, Inc.			
	DG	WO	01/77304	A	10-18-2001	GenVec, Inc.			
	DH	WO	01/92549	A	12-06-2001	GenVec, Inc.			
	DI	WO	02/29388	A	04-11-2002	GenVec, Inc.			


OTHER - NON PATENT LITERATURE DOCUMENTS									
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.						Translation Provided**	
								Yes	No
	DJ	AVRAHAM et al., "Prospects for gene therapy in hearing loss," <i>J. Basic Clin. Physiol. Pharmacol. (Israel)</i> , 14 (2): 77-83 (2003).							
	DK	BAYLOR COLLEGE OF MEDICINE, "MATH1 signal heralds process of differentiation in intestinal lining," <i>Biocompare News</i> , December 6, 2001. (Retrieved from the internet on December 10, 2001.)							

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known	
			Application Number	10/586,072
			Filing Date	
			First Named Inventor	BROUGH, Douglas E.
			Group Art Unit	1632
			Examiner Name	
Sheet	6	of	11	Attorney Docket Number 253625


OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	DL	BEN-ARIE et al., "Abnormal cerebellar development in mice lacking the murine homolog of the Drosophila proneural gene atonal," <i>Am. J. Hum. Genet.</i> , 59 (4 Suppl.): A46 (Abstract #232) (1996).		
	DM	BEN-ARIE et al., "Evolutionary conservation of sequence and expression of the bHLH protein Atonal suggests a conserved role in neurogenesis," <i>Hum. Mol. Genet.</i> , 5 (9): 1207-1216 (1996).		
	DN	BEN-ARIE et al., " <i>Math 1</i> is essential for genesis of cerebellar granule neurons," <i>Nature</i> , 390: 169-172 (November 13, 1997).		
	DO	BERMINGHAM et al., " <i>Math1</i> : An essential gene for the generation of inner ear hair cells," <i>Science</i> , 284: 1837-1841 (June 11, 1999).		
	DP	BERMINGHAM-McDONOGH, "Hair cell regeneration: winging our way towards a sound future," <i>Curr. Opin. Neurobiol.</i> , 13: 119-126 (2003).		
	DQ	BROUGH et al., "Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo," <i>J. Virol.</i> , 71 (12): 9206-9213 (December 1997).		
	DR	CAREY et al., "Hair cell regeneration and recovery of the vestibuloocular reflex in the avian vestibular system," <i>J. Neurophysiol.</i> , 76 (5): 3301-3312 (November 1996).		
	DS	CHADER, "Multipotential differentiation of human Y-79 retinoblastoma cells in attachment culture," <i>Cell Different.</i> , 20 (2-3): 209-216 (1987).		
	DT	CHEN et al., "The role of <i>Math1</i> in inner ear development: Uncoupling the establishment of the sensory primordium from hair cell fate determination," <i>Development</i> , 129 (10): 2495-2505 (2002).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/586,072	
			Filing Date		
			First Named Inventor	BROUGH, Douglas E.	
			Group Art Unit	1632	
			Examiner Name		
Sheet	7	of	11	Attorney Docket Number	253625


OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	DU	CHIEN et al., "Neuronal type information encoded in the basic-helix-loop-helix domain of proneural genes," <i>Proc. Natl. Acad. Sci. USA</i> , 93: 13239-13244 (November 1996).		
	DV	CRAWFORD-MIKSZA et al., "Analysis of 15 Adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues," <i>J. Virol.</i> , 70 (3): 1836-1844 (1996).		
	DW	CREA et al., "Chemical synthesis of genes for human insulin," <i>Proc. Natl. Acad. Sci. USA</i> , 75 (12): 5765-5769 (December 1978).		
	DX	DOOLING, "Recovery of hearing and vocal behavior after hair-cell regeneration," <i>Proc. Natl. Acad. Sci. USA</i> , 94: 14206-14210 (December 1997).		
	DY	EINFELD et al., "Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions," <i>J. Virol.</i> , 75 (23): 11284-11291 (December 2001)		
	DZ	GRAHAM et al., "Characteristics of a human cell line transformed by DNA from human adenovirus type 5," <i>J. Gen. Virol.</i> , 36: 59-72 (1977).		
	EA	GUO et al., "The nuclear matrix protein NMP-1 is the transcription factor YY1," <i>Proc. Natl. Acad. Sci. USA</i> , 92: 10526-10530 (1995).		
	EB	HASSON et al. "Expression in cochlea and retina of myosin VIa, the gene product defective in Usher syndrome type 1B," <i>Proc. Natl. Acad. Sci. USA</i> , 92: 9815-9819 (October 1995).		
	EC	HAWKINS, "Comparative otopathology: aging, noise, and ototoxic drugs," <i>Adv. Otorhinolaryngol.</i> , 20: 125-141 (1973)		
	ED	ITAKURA et al., "Expression in <i>Escherichia coli</i> of a chemically synthesized gene for the hormone somatostatin," <i>Science</i> , 198, (4321): 1056-1063 (1977).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/586,072	
			Filing Date		
			First Named Inventor	BROUGH, Douglas E.	
			Group Art Unit	1632	
			Examiner Name		
Sheet	8	of	11	Attorney Docket Number	253625


OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	EE	JARMAN et al., "Atonal is a proneural gene that directs chordotonal organ formation in the drosophila peripheral nervous system," <i>Cell</i> , 73: 1307-1321 (July 2, 1993).		
	EF	JERO et al., "Cochlear gene delivery through an intact round window membrane in mouse," <i>Hum. Gene Ther.</i> , 12: 539-548 (March 20, 2001).		
	EG	KANZAKI et al., "From gene identification to gene therapy," <i>Audiol. Neurotol.</i> , 7 (3): 161-164 (2002).		
	EH	KAWAMOTO et al., "Math1 gene transfer generates new cochlear hair cells in mature guinea pigs <i>in vivo</i> ," <i>J. Neurosci.</i> , 23 (11): 4395-4400 (June 1, 2003).		
	EI	KAWAMOTO et al., "The functional and structural outcome of inner ear gene transfer via the vestibular and cochlear fluids in mice," <i>Mol. Ther.</i> , 4 (6): 575-585 (2001).		
	EJ	LAUGHLIN et al., "Closing of infectious adeno-associated virus genomes in bacterial plasmids," <i>Gene</i> , 23: 65-73 (1983).		
	EK	LUEBKE et al., "A modified adenovirus can transfect cochlear hair cells <i>in vivo</i> without compromising cochlear function," <i>Gene Ther.</i> , 8: 789-794 (2001).		
	EL	LUEBKE et al., "Cochlear function and transgene expression in the guinea pig cochlea, using adenovirus- and adeno-associated virus-directed gene transfer," <i>Hum. Gene Ther.</i> , 12: 773-781 (May 1, 2001).		
	EM	MARINOVIC et al., "Ubiquitin (<i>UbC</i>) expression in muscle cells is increased by glucocorticoids through a mechanism involving Sp1 and MEK1*," <i>J. Biol. Chem.</i> , 277 (19): 16673-16681 (May 10, 2002).		
	EN	MILLAR et al., "Molecular mechanisms regulating hair follicle development," <i>J. Invest. Dermatol.</i> , 118: 216-225 (2002).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/586,072	
			Filing Date		
			First Named Inventor	BROUGH, Douglas E.	
			Group Art Unit	1632	
Examiner Name					
Attorney Docket Number	253625				
Sheet	9	of	11		


OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided*		
			Yes	No	
	EO	MONTCOUQUIOL et al., "Intracellular signals that control cell proliferation in mammalian balance epithelia: Key roles for phosphatidylinositol-3 kinase, mammalian target of rapamycin, and S6 kinases in preference to calcium, protein kinase C, and mitogen-activated protein kinase," <i>J. Neurosci.</i> , 21 (2): 570-580 (January 15, 2001).			
	EP	MORI et al., "Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization," <i>J. Cell. Physiol.</i> , 188: 253-263 (2001).			
	EQ	PIGNOLO et al., "Senescent WI-38 cells fail to express EPC-1, a gene induced in young cells upon entry into the G0 state," <i>J. Biol. Chem.</i> , 268 (12): 8949-8957 (April 25, 1993).			
	ER	SABATÉ et al., "Adenovirus for neurodegenerative diseases: in vivo strategies and ex vivo gene therapy using human neural progenitors," <i>Clin. Neurosci.</i> , 3: 317-321 (1996).			
	ES	SCHWARZE et al., "In vivo protein transduction: delivery of a biologically active protein in the mouse," <i>Science</i> , 285: 1569-1572 (September 3, 1999).			
	ET	SHOU et al., "Robust generation of new hair cells in the mature mammalian inner ear by adenoviral expression of <i>Hath1</i> ," <i>Mol. Cell. Neurosci.</i> , 23 (2): 169-179 (June 2003).			
	EU	STAECKER et al., "Brain-derived neurotrophic factor gene therapy prevents spiral ganglion degeneration after hair cell loss," <i>Otolaryngol. Head Neck Surg.</i> , 119: 7-13 (1998).			
	EV	STAECKER et al., "Gene expression in the mammalian cochlea: a study of multiple vector systems," <i>Acta Otolaryngol.</i> , 121: 157-163 (2001).			
	EW	STÖVER ET AL., "Cochlear gene transfer: round window versus cochleostomy inoculation," <i>Hearing Res.</i> , 136: 124-130 (1999).			

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/586,072	
			Filing Date		
			First Named Inventor	BROUGH, Douglas E.	
			Group Art Unit	1632	
			Examiner Name		
Sheet	10	of	11	Attorney Docket Number	253625


OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	EX	SUN et al., "Transcriptional regulation of atonal during development in the <i>Drosophila</i> peripheral nervous system," <i>Development</i> , 125: 3731-3740 (1998).		
	EY	SUZUKI et al., "Effect of transgenic GDNF expression of gentamicin-induced cochlear and vestibular toxicity," <i>Gene Ther.</i> , 7 (12): 1046-1054 (June 2000).		
	EZ	TONG et al., "Genomic organization of the JEM-1 (BLZF1) gene on human chromosome 1q24: molecular cloning and analysis of its promoter region," <i>Genomics</i> , 69 (3): 380-390 (November 2000).		
	FA	TONG et al., "Expression patterns of the <i>JEM-1</i> gene in normal and tumor cells: ubiquity contrasting with a faint, but retinoid-induced, mRNA expression in promyelocytic NB4 cells," <i>Leukemia</i> , 12 (11): 1733-1740 (1998).		
	FB	VAN BEUSECHEM et al., "Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished," <i>J. Virol.</i> , 76 (6): 2753-2762 (March 2002).		
	FC	WAGNER et al., "Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type I," <i>Proc. Natl. Acad. Sci. USA</i> , 78: 144-145 (1981)		
	FD	WANG et al., "Second generation adenovirus vectors," <i>Nature Med.</i> , 2 (6): 714-716 (1996).		
	FE	WILLIAMS et al., "Structure/function analysis on interleukin-2-toxin (DAB ₄₈₆ -IL-2)," <i>J. Biol. Chem.</i> , 265 (20): 11885-11887 (July 15, 1990).		
	FF	ZHENG et al., "Overexpression of <i>Math1</i> induces robust production of extra hair cells in postnatal rat inner ears," <i>Nature Neurosci.</i> , 3 (6): 580-586 (June 2000).		
	FG	ZINE et al., " <i>Hes1</i> and <i>Hes5</i> activities are required for the normal development of the hair cells in the mammalian inner ear," <i>J. Neurosci.</i> , 21 (13): 4712-4720 (July 1, 2001).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/586,072	
			Filing Date		
			First Named Inventor	BROUGH, Douglas E.	
			Group Art Unit	1632	
			Examiner Name		
Sheet	11	of	11	Attorney Docket Number	253625

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	FH	ZINE, "Molecular mechanisms that regulate auditory hair-cell differentiation in the mammalian cochlea," <i>Mol. Neurobiol.</i> , 27 (2): 223-237 (April 2003).		
	FI	ZUO, "Transgenic and gene targeting studies of hair cell function in mouse inner ear," <i>J. Neurobiol.</i> , 53 (2): 286-305 (November 2002).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.